drugset / Trial / NCT06494761
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.
Timeline
- Start
- 2024-07-30
- Primary completion
- 2024-10-16
- Completion
- 2024-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 1 mg | Oral |
| Subject | Omeprazole | Other / unclassified | 20 mg | — |
| Subject | Repaglinide | Small molecule | 0.5 mg | — |
| Subject | Zongertinib | Small molecule | 120 mg | Oral |
Indications
No indication recorded.